Schrodinger Strengths, Domain Expertise, and Key Differentiators
Schrödinger is an American software company that develops chemical simulation software for use in pharmaceutical, biotechnology, and materials science research. The company's full product offerings range from general molecular modelling programs to a comprehensive suite of drug design software, as well as a state-of-the-art suite for materials research.Schrödinger stands out as one of the earliest software providers to aggressively pursue cloud computing as a vehicle to speed up the process of finding and developing lead compounds.
Schrodinger Recent Developments
In February 2018, Schrödinger dedicated to revolutionizing drug discovery through advanced computational methods, trough Schrödinger Cryo-EM Initiative (SCI) to develop breakthrough medicines leveraging cryo-electron microscopy (Cryo-EM) technology and Schrödinger’s leading drug discovery platform.
In June 2018, Schrödinger contributed in a 2D coordinate generation tool, to the latest release of RDKit, an open-source cheminformatics toolkit.
In addition to developing the 2D coordinate generation tool, Schrödinger has also utilized RDKit to develop an open-source GPU-enabled similarity search tool and continued to support and improve both of these currently available tools.
Schrödinger’s open-source product, PyMOL, now contains RDKit-based plugins, with plans for further integration.
Schrödinger is also proud to contribute to the open-source Python library toolchain DeepChem, a project developed through academic and industrial collaborators, which heavily uses RDKit.
Schrodinger Customers in ARTW Customer Database
Leveraging a rigorous data-centric research methodology, APPS RUN THE WORLD asks the simple question: Who’s buying Schrodinger applications and why? And we provide the answers – supported by decades of research – to our clients around the world. Our Customer database has over 100 data fields that detail company usage of Schrodinger and other enterprise apps by function, customer size, industry, location, implementation status, partner involvement, Line of Business Key Stakeholders and IT decision makers contact details. List of Verified Schrödinger software release 2017-1, customers.
Ownership: - NASDAQ SDGR
Number of Employees: 400
Key Verticals: Life Sciences,
Schrodinger Key Enterprise and Cloud Applications
Schrödinger software release 2017-1,
Schrodinger Revenues, $M:
|Type/Year||2018||2019||YoY Growth, %|
|Total Revenues, $M||Subscribe||Subscribe||Subscribe|
|Enterprise Applications Revenues, $M||Subscribe||Subscribe||Subscribe|
|Cloud Applications Revenues, $M||Subscribe||Subscribe||Subscribe|
* Enterprise Applications Revenues = License + Support & Maintenance + SaaS
** All revenue figures are estimates based on public records, Cloud and Non-Cloud business models in Apps Run The World's vendor database, and annual survey results including vendor feedback.
Schrodinger Revenue Breakdown By Type, $M:
|Type||License||Services||Hardware||Support & Maintenance||SaaS|
|% of Total Revenues||Subscribe||Subscribe||Subscribe||Subscribe||Subscribe|
Schrodinger Enterprise Applications Revenues By Functional Markets, $M:
Schrodinger Enterprise Applications Revenues By Verticals, $M:
Schrodinger Revenues By Region, $M
|Region||% of Total Revenues||2019 Total Revenues, $M||2019 Enterprise Applications Revenues, $M||2019 Cloud Applications Revenues, $M|
Schrodinger Direct vs Indirect sales
|Region||Direct Sales||Indirect Sales||Total|
Schrodinger Customers - Breakdown by Geo, Size, Vertical and Product
No. of Schrodinger Customers: 2400
No. of Schrodinger Enterprise Applications Customers: 2400
No. of Schrodinger Cloud Customers: x
No. of Schrodinger Cloud Subscribers: x
Schrödinger has 1150 commercial customers (including all top 30 pharma companies) and more than 1250 academic and government customers. In the past two years, Materials Science Suite was selected by Boeing Company, Seoul National University and others.
Schrodinger Market Opportunities, M&A and Geo Expansions
In March 2020, Schrödinger expanded collaboration with AstraZeneca focused on refining a biologics modeling solution with the aim of speeding up the development of antibody and protein-based therapeutic candidates. The multi-year agreement extends an existing collaboration in which AstraZeneca is deploying Schrödinger’s computational platform to advance small molecule drug discovery efforts. The new collaboration is aimed at enhancing Schrödinger’s Free Energy Perturbation (FEP+) technology for the optimization of key properties of biologics, such as affinity and selectivity, with particular focus on binding affinity.
In May 2018, Schrödinger dedicated to revolutionizing drug discovery through advanced computational methods, trough collaboration with Canada’s national Centre for Drug Research and Development (CDRD),. This collaboration resulted with development of novel immuno-oncology monoclonal antibodies and other cancer biologics. CDRC provided a portfolio of targeted antibodies and Schrödinger have applied its advanced computation platform to prioritize these drug candidates and otherwise accelerate discovery. The initial project has involved an immune checkpoint target that is present on cancer stem cells.
Schrodinger Risks and Challenges
Consolidation among big pharmas could impact long-term growth of Schrodinger.
Schrodinger Ecosystem, Partners, Resellers and SI
In January 2020, Schrödinger and Bayer partnered to develop a comprehensive de novo design solution with the objective to accelerate the discovery of innovative high-quality drugs. The technology is expected to be capable of enumerating, screening, and scoring billions of synthetically feasible, virtual compounds supporting the identification and optimization of potential new therapeutic candidates. Under the terms of the agreement, Schrödinger is expected to receive about €10 million. The de novo design software will integrate the power of Schrödinger’s molecular design technology, which relies on physics-based modeling augmented by machine learning, with Bayer’s proprietary in silico models predicting compound absorption, distribution, metabolism, excretion, toxicity (ADMET) and chemical synthesizability. The new software will be built on Schrödinger’s enterprise informatics solution, LiveDesign, and is intended to rapidly design large numbers of molecules and predict their properties.
In March 2020, Schrödinger entered into a three-year agreement with Google Cloud to substantially increase the speed and capacity of its physics-based computational platform for drug discovery. As part of the agreement, Schrödinger has selected Google Cloud as the preferred cloud platform for its leading simulation software.
Schrödinger engages in a wide range of drug discovery services and collaborations. To date Schrödinger has engaged in over 100 service agreements and collaborations, many of which have achieved success-based milestones, including successful progression to clinical trials.
In June 2018, Schrӧdinger made a partnership with i2Learning to expose middle schoolers to advanced simulation software. This partnership is part of Schrӧdinger’s STEM outreach program, which seeks to promote the company’s goal to make science accessible, relatable, and creative. By working with i2Learning, Schrӧdinger enabled students and educators to gain real-world experience with state-of-the-art computational tools. Schrodinger and i2Learning ware working collaboratively to increase excitement about and exposure to science at a young age.
Among Schrödinger, partners are Altoris, Amazon Web Services (AWS), ChemAxon, Cycle Computing, D.E. Shaw Research, eMolecules, Exxact, John McNeil & Co and others.
Schrodinger Cloud Infrastructure Insights
Subscribe to read more about:
- Schrodinger Public Cloud and Infrastructure (IaaS)
- Schrodinger Platform (PaaS)
- Schrodinger Application Delivery
- Schrodinger Private Cloud and Data Centers
Data used in research reports are derived from publicly available documents, continuous surveys of applications vendors, customers, resellers, Independent Software Vendors, systems integrators and other verifiable sources.
Vendor shares and market forecast results are based on a combination of existing databases as well as demand side and supply side research conducted throughout the year with validation from vendors, customers, channel partners and documentations such as earnings releases and 10Q and 10K filings, vertical industry studies, regional and country-level statistics from public and private institutions(i.e. colleges, universities, government agencies and trade associations).
For additional information on our methodologies, here's the link:https://www.appsruntheworld.com/About Us
Copyright © 2021, APPS RUN THE WORLD